Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Biomarkers in Solid Tumors: Recent Advances and Challenges
share announcement

Biomarkers in Solid Tumors: Recent Advances and Challenges

A Special Issue of Biomedicines (ISSN 2227-9059) belonging to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 561

Editor

Dr. Raghu Sinha

E-Mail Website
Guest Editor
Department of Molecular and Precision Medicine, Penn State College of Medicine, Penn State Cancer Institute, Penn State Centre for Research on Tobacco and Health, Hershey, PA, USA
Interests: anti-cancer mechanisms of organo-selenium compounds; cancer biomarkers; chemoprevention; cancer therapy; dietary manipulations; tobacco research; inflammation; systems biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The landscape of solid tumor management has been fundamentally transformed by the discovery and clinical integration of biomarkers. From early detection and risk stratification to predicting treatment response and monitoring disease progression, biomarkers now serve as indispensable tools in precision oncology. The advent of high-throughput technologies, including next-generation sequencing, liquid biopsy and multi-omics approaches, have exponentially expanded our ability to uncover novel molecular signatures. These advances have enabled the identification of predictive biomarkers for targeted therapies and immunotherapies, ushering in an era of personalized medicine that offers improved outcomes for patients with cancers such as brain, breast, colorectal, lung, melanoma, pancreatic and prostate cancer.

This Special Issue invites original research and reviews that explore both cutting-edge advances and persistent challenges in solid tumor biomarkers. By addressing these critical issues, we aim to accelerate the path toward more precise, accessible and effective biomarker-based oncology.

Dr. Raghu Sinha
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • liquid biopsy
  • diagnosis
  • prognosis
  • cancer
  • multi-omics
  • next-generation sequencing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 301 KB  
Article
The vWF/ADAMTS13 Ratio as a Potential Marker of Endotheliopathy in Malignancies
by Alexander Vorobev, Victoria Bitsadze, Jamilya Khizroeva, Antonina Solopova, Maria Tretyakova, Nilufar Gashimova, Kristina Grigoreva, Irina Kalashnikova, Natalia Makatsariya, Vlada Rubashkina, Yana Sulina, Aidanhanum Iskenderova, Alexandra Antonova, Dmitry Utkin, Jean-Christophe Gris, Ismail Elalamy, Grigoris Gerotziafas and Alexander Makatsariya
Biomedicines 2026, 14(9), 2078; https://doi.org/10.3390/biomedicines14092078 - 15 Sep 2026
Abstract
Background: Endothelial activation and thromboinflammation play an important role in cancer-associated thrombosis. An imbalance between von Willebrand factor (vWF) and its physiological regulator ADAMTS13 may reflect the development of a prothrombotic endothelial state in patients with malignancies. However, the dynamics of the vWF-ADAMTS13 [...] Read more.
Background: Endothelial activation and thromboinflammation play an important role in cancer-associated thrombosis. An imbalance between von Willebrand factor (vWF) and its physiological regulator ADAMTS13 may reflect the development of a prothrombotic endothelial state in patients with malignancies. However, the dynamics of the vWF-ADAMTS13 axis during chemotherapy and thromboprophylaxis remain insufficiently characterized. Objectives: To characterize the vWF-ADAMTS13 axis as a potential laboratory marker of endotheliopathy in patients with gynecologic malignancies and to assess its dynamics during chemotherapy and thromboprophylaxis with low-molecular-weight heparin (LMWH). Materials and Methods: This prospective comparative study included 74 patients with stage I–III gynecologic malignancies undergoing chemotherapy after surgical treatment. Group I comprised 34 patients with a history of thrombotic complications (VTE), including 23 patients with ovarian cancer and 11 with cervical adenocarcinoma. Group II included 40 patients without previous VTE, including 20 patients with ovarian cancer and 20 with cervical adenocarcinoma. The control group consisted of 25 healthy women. Plasma vWF levels, ADAMTS13 antigen and functional activity, ADAMTS13 inhibitor levels, and the vWF/ADAMTS13 ratio were assessed before chemotherapy and after 1–2 chemotherapy cycles. Patients in Group I additionally received thromboprophylaxis with nadroparin calcium. Results: Before chemotherapy, an imbalance of the vWF-ADAMTS13 axis was observed in patients with malignancies compared with healthy controls and was most pronounced in patients with a history of thrombosis. The vWF/ADAMTS13 ratio was 0.65 in controls, 1.02 and 0.84 in patients without previous VTE with ovarian and cervical cancer, respectively, and 1.59 and 1.34 in the corresponding subgroups with a history of thrombosis (p < 0.05). After 1–2 chemotherapy cycles, the vWF–ADAMTS13 axis showed a further shift toward imbalance, characterized by increased vWF levels, decreased ADAMTS13 antigen levels and functional activity, and increased ADAMTS13 inhibitor concentrations. The vWF/ADAMTS13 ratio increased to 2.04 in patients with ovarian cancer and to 1.65 in those with cervical cancer and a history of thrombosis. In Group I, the subsequent assessment following chemotherapy and LMWH thromboprophylaxis demonstrated partial reversal of these changes: ADAMTS13 antigen levels increased, while vWF levels and ADAMTS13 inhibitor concentrations decreased, and the vWF/ADAMTS13 ratio declined from 2.04 to 1.30 in ovarian cancer and from 1.65 to 1.14 in cervical cancer. Conclusions: The vWF-ADAMTS13 axis is markedly altered in patients with gynecologic malignancies, including those without previous VTE, with the most pronounced imbalance observed in patients with a history of thrombosis. The post-chemotherapy assessment demonstrated a further shift toward imbalance, whereas the subsequent assessment following chemotherapy and LMWH thromboprophylaxis in Group I showed partial reversal of these changes. The vWF/ADAMTS13 ratio may represent a potential integrative and dynamic marker of endothelial–hemostatic imbalance in patients with gynecologic malignancies. Full article
(This article belongs to the Special Issue Biomarkers in Solid Tumors: Recent Advances and Challenges)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop